Oern Stuge MD, MBA International Executive with 30+ Years of Experience Is Appointed to Median Technologies Board of Directors

June 25, 2020

Oern Stuge MD, MBA, has joined Median Technologies Board of Directors, chaired by Oran Muduroglu. This appointment was approved during the ordinary and extraordinary shareholder meeting, held on June 19th.

Oern Stuge brings to Median his tremendous expertise in the life sciences industry as well as his unique vision and experience in enterprise development including Go to Market strategy and Medtech company growth.

“Oern’s vast experience and knowledge of Medtech companies will further enhance Median’s leadership position in the field of AI-based non-invasive imaging biomarkers and maximize our success in developing and implementing our Go to Market and business growth strategies. His appointment as a board member is a major milestone furthering our intent to become the leader of imaging biomarkers and bring our AI-based imaging platform iBiopsy® to the biopharmaceutical industry and healthcare market as well”, Fredrik Brag, CEO of Median Technologies said.

“Oern’s unique expertise and strategic vision are great assets for our company. As we rapidly enter the era of precision and predictive medicine, imaging biomarkers are going to become key in better understanding disease at the patient level in a non-invasive and personalized way. The stake is tremendous as it will enable clinicians to deliver personalized therapies to patients in need and complement or sometimes replace biopsies. We are thrilled to welcome Oern as a member of our Board of Directors.”

“I am thrilled to join the Board of Directors at Median Technologies, and the impressive team the CEO Fredrik Brag, has built. I am confident the company will continue to build significant value for its stakeholders”, Dr. Stuge added.

Stuge is an international executive with 30+ years of experience in the Life Science sector.

He is currently Chairman of Orsco Lifesciences AG. Through this company, he holds several executive and non-executive board memberships and advisory roles. During the last 9 years, Dr. Stuge has participated in Enterprise Development of different companies and successfully sold/listed 7 of them: 5 of the portfolio companies have been successfully sold, following improved strategic positioning and operation, 2 of the portfolio companies have successfully launched their IPOs (Euronext Paris / ESM, Dublin, NASDAQ, Stockholm).

Prior to founding ORSCO, Dr. Stuge worked for 12 years for Medtronic, Inc. in different roles including Senior Vice President (SVP) and President EMEA, Canada and Emerging Markets, and SVP and President Cardiac Surgery. He was a member of the Medtronic Executive Committee and Operating Committee. Dr. Stuge led a successful transformation of Medtronic’s global Cardiac Surgery business. Under his leadership, Medtronic founded the Structural Heart Division and launched the first commercially available percutaneous heart valve in the world.

Prior to Medtronic, Oern held senior positions at Abbott Laboratories as well as at a Norwegian start-up as a CEO. He began his career as a practicing physician. He has an MD from the University of Oslo, and an MBA from IMD in Lausanne.

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.